# Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

> **NCT07115004** · PHASE3 · RECRUITING · sponsor: **Vega Therapeutics, Inc** · enrollment: 60 (estimated)

## Conditions studied

- Von Willebrand Disease (VWD)

## Interventions

- **DRUG:** VGA039

## Key facts

- **NCT ID:** NCT07115004
- **Lead sponsor:** Vega Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2028-10
- **Final completion:** 2028-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07115004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07115004, "Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07115004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*